Opinion|Videos|September 3, 2025
Discussing Baricitinib for Alopecia Areata
Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment for severe alopecia areata (AA).
Advertisement
Video content above is prompted by the following:
- McMichael: Baricitinib became the first systemic treatment for severe AA after the
BRAVE-AA1 and BRAVE-AA2 phase 3 trials were released. What did the data show in terms of safety and efficacy that led to FDA approval in 2022?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Final Thoughts on Arrhythmia Management
September 23rd 2025
- Designing Value-Based Care Programs Around Arrhythmias
September 23rd 2025
- The Utility of Implantable Cardiac Rhythm Monitors
September 23rd 2025
- Atopic Dermatitis Clinical Trial Representation: Addressing Historical Gaps
September 19th 2025
- BCMA-Targeted Bispecific Antibodies: Navigating the New Frontier of Myeloma
September 17th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Trump Administration Flags Potential Link Between Prenatal Acetaminophen Use, Autism
2
Subtle Brain Changes May Drive Disability in Multiple Sclerosis Beyond Visible Lesions
3
Medicare Beneficiaries With Near Low Income Face Highest Health Care Affordability Challenges
4
Childhood Cancer Awareness Month Spotlights Barriers That Persist in Care
5